Zimmer Holdings PT Raised to $102.00 at Jefferies Group (ZMH)
Stock analysts at Jefferies Group lifted their price objective on shares of Zimmer Holdings (NYSE:ZMH) from $87.00 to $102.00 in a report issued on Friday, Stock Ratings Network reports. Jefferies Group’s price target indicates a potential upside of 9.63% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at BMO Capital Markets raised their price target on shares of Zimmer Holdings from $100.00 to $108.00 in a research note to investors on Friday. Separately, analysts at Deutsche Bank raised their price target on shares of Zimmer Holdings from $98.00 to $100.00 in a research note to investors on Friday. Finally, analysts at Cowen and Company raised their price target on shares of Zimmer Holdings from $84.00 to $96.00 in a research note to investors on Friday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $93.48.
Zimmer Holdings (NYSE:ZMH) traded up 0.14% on Friday, hitting $93.17. The stock had a trading volume of 210,828 shares. Zimmer Holdings has a 52-week low of $72.24 and a 52-week high of $97.86. The stock has a 50-day moving average of $93.9 and a 200-day moving average of $87.08. The company has a market cap of $15.930 billion and a price-to-earnings ratio of 23.58.
Zimmer Holdings (NYSE:ZMH) last announced its earnings results on Friday, January 31st. The company reported $1.36 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.62 by $0.26. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.22 billion. Analysts expect that Zimmer Holdings will post $5.71 EPS for the current fiscal year.
Zimmer Holdings, Inc (NYSE:ZMH) designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.